Leading Life Science Innovation

MG

MGI Statement

MGI and its affiliates today announce that they have settled all outstanding litigation in

the United States with Illumina. Under the terms of the parties' settlement agreement,

each party will drop any challenges to the Court's judgments entered in the Northern

District of California and the District of Delaware, with a net payment to CGI of \$325

Million that reflects the parties' damages awarded in such judgments.

In addition, the parties will dismiss their pending antitrust litigation in the Northern

District of California. Illumina will receive a paid-up, license to the 2 Color family of

U.S. patents and U.S. patent applications that CGI and MGI asserted in Delaware. As

previously announced, MGI will begin selling its CoolMPS platform by August 2022

and can begin selling its StandardMPS products by January 2023.

The parties also agree to a three-year period of peace with respect to claims of U.S.

patent infringement and violations of any antitrust or unfair competition laws of the

United States, during which time they will not sue each other or respective customers

in the United States or accrue liability for existing platforms.

MGI 14 July 2022

09359-00003/13503293.1



华大智造声明

华大智造 (MGI) 及其关联公司今天宣布,与因美纳 (Illumina) 就美国境内的所 有未决诉讼达成和解。根据协议条款,双方将不再对加州北部地区法院和特拉华 州地区法院的诉讼判决结果提出异议。基于此,因美纳将向华大智造支付 3.25 亿 美元的净赔偿费。

此外,华大智造将撤销在加州北部地区法院对因美纳的反垄断诉讼。因美纳将获 得华大智造及其子公司 CG 的"双色测序技术 (Two-color sequencing technology)" 系列专利授权。如同此前所宣布的,华大智造将于2022年8月开始在美国销售 其基于 CoolMPS 技术的相关测序产品, 并于 2023 年 1 月开始销售 StandardMPS 相关测序产品。

双方还同意, 未来三年, 在美国境内将不会就专利侵权以及违反美国反垄断法或 不正当竞争起诉对方及其客户,也不对现有测序平台可能造成的损失进行索赔。

> 华大智造 2022年7月*日